title: Calcium channel receptor sites for (+)-[3H]PN 200-110 in coronary artery.
abstract: The receptor sites for 1,4-dihydropyridine (DHP) Ca++ channel antagonists in porcine coronary artery were identified and characterized by a binding assay using (+)-[3H]PN 200-110 as a radioligand. Specific (+)-[3H]PN 200-110 binding in porcine coronary artery was saturable, reversible and of high affinity (Kd = 0.24 nM) and it showed a pharmacological specificity as well as stereoselectivity which characterized the receptor sites for DHP Ca++ channel antagonists. DHP antagonists competed for the (+)-[3H]PN 200-110 binding in order: PN 200-110 greater than mepirodipine greater than nisoldipine greater than nicardipine greater than nitrendipine greater than nimodipine greater than nifedipine greater than (-)-PN 200-110. (+)-PN 200-110 was approximately 140 times as potent as the (-)-isomer. The potencies (PKi) of these eight DHP Ca++ channel antagonists in competing for (+)-[3H]PN 200-110 binding sites in porcine coronary artery correlated well with their pharmacological potencies. Specific (+)-[3H]PN 200-110 binding in the coronary artery was enhanced by d-cis-diltiazem and was inhibited incompletely by verapamil and D-600. In EDTA-pretreated coronary artery, the maximal number of binding sites for specific (+)-[3H]PN 200-110 binding was reduced (80%) markedly, and it was restored to the untreated level by the addition of Ca++ and Mg++.(ABSTRACT TRUNCATED AT 250 WORDS)
authors: Department of Biopharmacy, School of Pharmaceutical Science, University of Shizuoka, Japan.
authors: S
authors: S
authors: Yamada
authors: R
authors: R
authors: Kimura
authors: Y
authors: Y
authors: Harada
authors: K
authors: K
authors: Nakayama
mesh_terms: D000818:Animals; D001665:Binding Sites; D002121:Calcium Channel Blockers / Q000378:metabolism* / Q000494:pharmacology; D015220:Calcium Channels; D002413:Cations, Divalent / Q000494:pharmacology; D003331:Coronary Vessels / Q000032:analysis*; D004110:Diltiazem / Q000494:pharmacology; D004492:Edetic Acid / Q000494:pharmacology; D005260:Female; D066298:In Vitro Techniques; D017275:Isradipine; D007700:Kinetics; D008297:Male; D010069:Oxadiazoles / Q000378:metabolism*; D011978:Receptors, Nicotinic / Q000032:analysis*; D013552:Swine; D014700:Verapamil / Q000494:pharmacology
chemical_list: D002121:Calcium Channel Blockers; D015220:Calcium Channels; D002413:Cations, Divalent; D010069:Oxadiazoles; D011978:Receptors, Nicotinic; D004492:Edetic Acid; D014700:Verapamil; D004110:Diltiazem; D017275:Isradipine